Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3347–3349.

https://doi.org/10.1182/blood-2022-164541

Published: 2022

Journal Articles

FLT3 Inhibitors Upregulate CXCR4 and E-Selectin Ligands and CD44 Via ERK Suppression in AML Cells, and Blockade of CXCR4 and E-Selectin Signaling with GMI-1359 Overcomes AML Resistance to Quizartinib in Vitro and In Vivo

Yannan Jia, Mahesh Basyal, Lauren B Ostermann, Kyung Hee Chang, Qi Zhang, William E. Fogler, John L. Magnani, Marina Konopleva, Weiguo Zhang, Michael Andreeff

Blood (2021) 138 (Supplement 1): 1171.

https://doi.org/10.1182/blood-2021-146573

Published: 2021

Journal Articles

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

Yannan Jia, Qi Zhang, Connie Weng, Cassandra L Ramage, Yuki Nishida, Mark Chao, Roy Louis Maute, Shelley Herbrich, Weiguo Zhang, Michael Andreeff, Naval Daver, Marina Konopleva

Blood (2021) 138 (Supplement 1): 510.

https://doi.org/10.1182/blood-2021-147479

Published: 2021

Journal Articles

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Yannan Jia, Qi Zhang, Weiguo Zhang, Michael Andreeff, Nitin Jain, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2021-147535

Published: 2021

Journal Articles

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Kyung Hee Chang, Tomasz Zal, Mahesh Basyal, Lauren Ostermann, Muharrem Muftuoglu, Po Yee Mak, Yannan Jia, Wenjing Tao, Malgorzata Anna Zal, William E. Fogler, John L. Magnani, Weiguo Zhang, Bing Z Carter, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2021-153661

Published: 2021

Journal Articles

Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy

Kyung Hee Chang, PhD, Muharrem Muftuoglu, Weiguo Zhang, MD PhD, Mahesh Basyal, BSc, Lauren B Ostermann, BS, William E. Fogler, PhD, John L. Magnani, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-141957

Published: 2020

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Weiguo Zhang, MD PhD, Kyung Hee Chang, PhD, Mahesh Basyal, BS, Yannan Jia, Lauren B Ostermann, BS, William E. Fogler, PhD, John L. Magnani, PhD, M Anna Zal, BS., MS, Tomasz Zal, PhDMSc, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140984

Published: 2020

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

Regulation of Erythroblast Protein Expression By an RNA Splicing Mechanism, Decoy Exon-Mediated Intron Retention

Marilyn Parra, Weiguo Zhang, PhD, Jonathan Vu, Mark DeWitt, John G Conboy, PhD

Blood (2019) 134 (Supplement_1): 3504.

https://doi.org/10.1182/blood-2019-131153

Published: 2019

Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1389.

https://doi.org/10.1182/blood-2019-122585

Published: 2019

Journal Articles

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Kotoko Yamatani, MD, Yoko Tabe, MD PhD, Kaori Saito, Haeun Yang, Yuko Murakami-Tonami, MD PhD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, PhD, Shigeo Yamaguchi, MD PhD, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 3944.

https://doi.org/10.1182/blood-2018-99-109957

Published: 2018

Journal Articles

Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

Michael Andreeff, MD PhD, Weiguo Zhang, MD PhD, Prasanna Kumar, PhD, Oleg Zernovak, MD, Naval G. Daver, MD, Takeshi Isoyama, PhD, Kouichi Iwanaga, D.V.M, PhD, Noriko Togashi, Takahiko Seki, PhD

Blood (2018) 132 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2018-99-115183

Published: 2018

Journal Articles

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

Yoko Tabe, MD PhD, Kotoko Yamatani, MD, Haeun Yang, Kaori Saito, Yuko Murakami-Tonami, MD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Masaki Hosoya, PhD, Kaoru Mogushi, PhD, Shigeo Yamaguchi, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil Shah, MD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2640.

https://doi.org/10.1182/blood-2018-99-113195

Published: 2018

Journal Articles

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Peter P. Ruvolo, PhD, Huaxian Ma, MS, Vivian Ruvolo, MS, Xiaorui Zhang, BS, Hong Mu, MD PhD, Tomoko Yasuhiro, Kohei Tanaka, Toshio Yoshizawa, PhD, Weiguo Zhang, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2018-99-112211

Published: 2018

Journal Articles

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hongying Zhang, MD, PhD, Charlie Ly, BS, Bin Yuan, Vivian Ruvolo, MS, Sujan Piya, PhD, Seemana Bhattacharya, PhD, Qi Zhang, PhD, Gautam Borthakur, MD, Venkata Lokesh Battula, PhD, Marina Y. Konopleva, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2018-99-116643

Published: 2018

Journal Articles

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 1441.

https://doi.org/10.1182/blood-2018-99-118028

Published: 2018

Journal Articles

Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML

Antonio Cavazos, MSc, Helen Ma, MS, Lina Han, PhD, Tianyu Cai, PhD, Qi Zhang, PhD MD, Karine Harutyunyan, PhD, Natalia Baran, PhD MD, Weiguo Zhang, MD PhD, Naval Daver, MD, Michael Andreeff, MD PhD, Amir Ashoorzadeth, PhD, Robert Anderson, MSc, PhD FNZIC, CChem, FRSC, Adam Patterson, PhD, Jeffrey B Smaill, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1342.

https://doi.org/10.1182/blood.V130.Suppl_1.1342.1342

Published: 2017

Journal Articles

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval Daver, MD, Rita Assi, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Tapan Kadia, MD, Jing Ning, PhD, Graciela Nogueras González, Sherry Pierce, BSN, BA, Mary Kelly, Weiguo Zhang, MD PhD, Dan Gombos, MD, Steven Kornblau, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 1344.

https://doi.org/10.1182/blood.V130.Suppl_1.1344.1344

Published: 2017

NARROW

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

FLT3 Inhibitors Upregulate CXCR4 and E-Selectin Ligands and CD44 Via ERK Suppression in AML Cells, and Blockade of CXCR4 and E-Selectin Signaling with GMI-1359 Overcomes AML Resistance to Quizartinib in Vitro and In Vivo

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Combined Blockage of E-Selectin and CXCR4 (GMI-1359) Enhances Anti-Leukemia Effect of FLT3 Inhibition (Sorafenib) and Protects Hematopoiesis in Pre-Clinical AML Models

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Regulation of Erythroblast Protein Expression By an RNA Splicing Mechanism, Decoy Exon-Mediated Intron Retention

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only